Introduction: Current cigarette smoking rates among older women remain problematic,
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Implications
To date, no studies have examined smoking behaviors across the menopausal transition.
In the present study, while menopausal transition status was not significantly related to transitions in smoking behavior, important relationships between sex hormones and depression were observed. Increased estradiol was associated with an increased likelihood of quitting regular smoking, while increased testosterone was associated with an increased likelihood of relapsing to regular smoking behavior. Higher depression scores were related to continued smoking and relapse to regular smoking behavior. These results highlight the need to develop interventions to target smoking cessation among women across the menopausal transition.
. 15 .5% in 2016 1 . However, smoking among older females remains relatively common; among women 45-64 years old, 16.8% report current smoking 1 . This is problematic given that cigarette smoking is the leading cause of preventable death and disease in the US and women experience a greater negative health burden when compared to men, with a greater risk of developing various cancers and cardiovascular diseases [2] [3] [4] [5] . Additionally, women smokers suffer from sex-sensitive and sex-specific health risks, especially associated with menopause, including earlier menopausal transition, increased risk of osteoporosis, impaired respiratory function, and more severe menopausal symptoms 2, [6] [7] [8] . Despite these increased health risks, women overall have poorer rates of smoking cessation, indicating that increased efforts are needed to understand and improve cessation rates 9 , specifically among older females.
One potential explanation for the observed differences in cessation rates may be the hormonal milieu. During menopause, endogenous levels of estradiol and progesterone initially fluctuate during the menopausal transition, but gradually decrease to low/stable levels in postmenopause 10 . Follicular stimulating hormone (FSH) levels, typically an indicator utilized in categorizing menopausal stage, increase substantially over the menopausal transition and remain elevated until later in life, while testosterone levels remain relatively stable across the transition [11] [12] [13] . The menopausal transition is typically divided into several stages based upon flucuating homorone levels and menstrual cycle length. Premenopause, is generally a time describing a women's reproductive years, which is often characterized by regular menses and low levels of FSH; the duration of premenopause is highly variable and may be further broken Among pre-menopausal women, there is evidence that progesterone is generally protective against smoking-related variables (e.g., decreased subjective reactivity, fewer puffs of cigarettes in laboratory settings), whereas estradiol is implicated in smoking behavior (e.g., relapse, continued smoking; for review see 15 ). However, it is worth noting that there is mixed evidence regarding the hormonal milieu, menstrual cycle, and smoking 15, 16 . As such, some studies, including one meta-analysis, have reported greater symptoms of withdrawal and craving during the luteal phase, when progesterone levels are highest 17 .
Regarding testosterone, smoking is associated with higher testosterone levels; however, the specific association among women smokers remains unclear and is understudied 18 . Among the few studies that have examined the role of testosterone in female smoking behavior 18 , higher concentrations of testosterone have been found in pre-menopausal smokers relative to female former smokers and non-smokers 19 . This pattern holds true for post-menopausal smokers, with higher levels of testosterone in current versus never smokers, which was associated with the A c c e p t e d M a n u s c r i p t 6 number of cigarettes smoked per day 20 . Additionally, high levels of testosterone were also observed among the postmenopausal former smokers included in one population-cohort study 20 .
Given the declining levels of endogenous estradiol and progesterone, as well as the stable levels of testosterone, postmenopause may be an advantageous time to make a cessation attempt.
However, to date the majority of the literature has focused on the impact of sex hormones and smoking behavior among pre-menopausal women 17 . In fact, little information is available regarding the impact of these endogenous hormones and their fluctuations on smoking cessation attempts during or after the menopausal transition 7 .
An additional factor that may explain changes in smoking behavior among older women is negative affect, specifically depressive symptoms. Women are at an increased risk of developing depressive symptoms during the menopausal transition, with a recent study showing that 31% experienced a period of persistent/recurrent depression and 9% endorsed a single major depressive episode, across a 13-year period during the menopausal transition 21, 22 . Such associations between the menopausal transition and depressive symptoms, may be associated with the fluctuating hormonal milieu across the transition 7, 22 . This likely has a meaningful impact for female smokers, as it is well established that negative affect impedes smoking cessation attempts among smokers [23] [24] [25] . However, little information is known regarding how depressive symptomatology impacts smoking behavior across the menopausal transition.
The current scant literature regarding smoking behaviors in older women leaves several important gaps to address in order to improve cessation outcomes in this population. For instance, to our knowledge, there are no studies examining smoking outcomes across the menopausal transition (pre-, early peri-, late peri-, and postmenopausal stages) and the impact of endogenous sex hormones and depression on such outcomes. Additionally, there is a need to The present study sought to investigate the effect of transitions across menopausal status (pre-, early peri-, late peri-, and postmenopausal stages) on the transition from regular smoking to non-regular/no smoking (i.e., quitting regular smoking behavior) as well as the reverse transition from non-regular/no smoking, among those endorsing ever smoking to regular smoking (i.e., relapse to regular smoking behavior). Additionally, we analyzed the impact of sex hormones, specifically, estradiol and testosterone, as well as depressive symptoms on these changes, while accounting for age.
The present study utilized data from the Study of Women's Health Across the Nation (SWAN). SWAN is a longitudinal, epidemiological study designed to capture the relevant biopsychosocial changes that impact females' health across the menopausal transition 26 . This dataset allowed investigation of the effects of menopausal status and endogenous sex hormones, as well as depression, on smoking. It was hypothesized that late peri-menopausal and postmenopausal status would be associated with an increased likelihood of quitting regular smoking in women followed across the transition and decreased likelihood of women relapsing to regularly smoking. It was hypothesized that increased levels of estradiol and testosterone would be associated with a decreased likelihood of quitting regular smoking and an increased likelihood of relapsing to regular smoking. Additionally, it was hypothesized that higher scores of depressive symptoms would be associated with a decreased likelihood of quitting regular smoking, as well as an increased likelihood of relapsing to regular smoking. 
METHODS

Data source
The data utilized in the present study are drawn from the publicly available SWAN datasets 26 . The study enrolled 3,302 participants from seven research centers across the US between 1996-1997. SWAN enrolled women who were between 42-52 years old, reported being pre-or early-perimenopausal (defined as reporting a menstrual period within the past 3 months),
did not take hormone medications in past three months and denied a total hysterectomy (participants reported an intact uterus and at least one ovary). These participants were then followed annually over ten years following the baseline visit with in-person examinations, which included biological measures (e.g., height, weight, blood draws), as well as and surveys assessing for various physical, biological, psychological and social changes. Additional information regarding the SWAN data and the specific variables it includes is available elsewhere 26 .
Data analysis
Data were analyzed using Stata Statistical Software 16.1 (StataCorp. 2016. College Station, TX: StataCorp LP). Annual datasets were merged, and variables were matched based upon a source-identification variable.
Menopausal status stage was coded each year during annual surveys 26 . Women were identified as pre-menopausal if they reported menses within the past 3 months with no change in menstruation patterns (e.g., no changes in regularity or menses occurring further or closer than previous menses). They were classified as early peri-menopausal if they experienced menses within the past 3 months, but identified decreased predictability between menses (e.g., changes in menses being further or closer apart; changes in variability or regularity of menses). Late peri- A c c e p t e d M a n u s c r i p t 9 menopausal women were classified as those who had reported no menses within the past 3-11 months. Finally, women reporting no menses for the past year were identified as postmenopausal.
Once categorized, women were not permitted to be categorized "backwards" in future visits 26 . In the SWAN dataset, women who reported taking hormonal therapies who had a hysterectomy/ovaries removed were classifed as "unknown due to [hormonal therapy] use," or "unknown due to hysterectomy," respectively 26 . Accordingly, these women were not included in analyses for the years their menopausal status was marked "unknown." Additionally, given the scope of this study, women who were currently pregnant/breastfeeding, were classified as such 26 and were excluded from the present analyses for the years they were pregnant/breastfeeding. It is important to note that the menopausal status definitions used in the SWAN study were based upon menopausal status definitions that were included in the Massachusetts Women's Health Study 27, 28 ; FSH levels were not used to categorize stages of the transititions for participants.
The present study included only participants who transitioned to postmenopausal status during the 10-year period. Smokers were identified from baseline data by responding yes to a query about smoking behavior at baseline (Have you ever smoked cigarettes regularly?;
response, yes/no). Transitions in smoking behavior were derived from an annual assessment of smoking behavior (Did you smoke regularly since last visit?; response, yes/no), beginning at Visit 1. Data was not censored at quitting and/or relapse to regular smoking behavior, in order to best capture subsequent transitions (e.g., if a participant relapsed, then, stopped smoking regularly, then relapsed to regular smoking again, both instances were counted in the analyses).
Random-effects logistic regression models with robust standard errors were calculated using the Xtlogic command in Stata: the association between menopausal status and transition A c c e p t e d M a n u s c r i p t 10 from regularly smoking to non-regular/no smoking (e.g., quitting regular smoking) between any waves of data collection, as well as the association between menopausal status and transition from non-regular/no smoking to regularly smoking between any waves of data collection, among those identified as "ever smokers" (e.g., relapse to regular smoking). Baseline age, age of post-menopausal status, and length of transition from early peri-to post-menopausal status were included in all models. Annual measures of hormonal assays, including estradiol and testosterone were included in the second and third models. Estradiol and testosterone results did not have normal distributions, and thus natural log transformed values were used. This strategy has been utilized in other analyses of SWAN hormonal data (e.g., 29, 30 ). Of note, FSH was not included in current analyses, due to multicollinearity with the menopausal transition variable. Depression symptoms were also evaluated annually, with the Center for Epidemiological StudiesDepression (CES-D) 31 , and were included in the third model.
RESULTS
Baseline data identified 1,397 females as being ever regular smokers. Of the identified baseline, ever regular smokers, the majority were White/non-Hispanic (54.4%; Black/African American, 30.60%, Hispanic, 6.70%, Asian/Asian American, 8.3%). Mean age at baseline was 45.84 years (SD=2.67 years).
Transition from smoking regularly to quitting regular smoking
There were no significant associations between menopausal status and the transition from smoking regularly to not regularly/not smoking. However, increased estradiol levels were associated with an increased likelihood of quitting regular smoking. Testosterone levels were not significantly related to the transition to quitting regular smoking. Additionally, increased depressive symptoms (measured via CESD) decreased one's likelihood of quitting regular smoking. See Table 1 for complete results. A c c e p t e d M a n u s c r i p t
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Transition from former smoker/not smoking regularly to smoking regularly Again, no significant association between menopausal status and the transition from nonregularly/no smoking, among former "ever smokers," to regular smoking (e.g., relapse)
were observed. Similarly, estradiol levels were not significantly related to transition to relapse to regular smoking. However, increased levels of testosterone and depression (measured via CESD)
were associated with an increased likelihood of relapsing. See Table 2 for complete results.
DISCUSSION
Given the scant literature investigating the menopausal transition and smoking outcomes to date 7 , the present study sought to explore the effect of menopausal status on smoking behavior. While our results did not demonstrate an association between the transition through menopause stages and quitting/relapsing of regular smoking behavior, the present results did illustrate that it is likely that other unique factors related to the menopausal transition are related to changes in smoking behavior.
One of these unique factors related to smoking outcomes across the menopausal transition is likely the hormonal milieu, given the previous evidence that endogenous sex hormone levels impact smoking cessation in pre-menopausal women 17 . In the current investigation, testosterone was related to an increased likelihood of relapse to regular smoking, with no significant effect on the likelihood of quitting regularly smoking behaviors. This supports previous literature that both male and female smokers, relative to non-smokers or former smokers, have higher levels of testosterone [18] [19] [20] . Thus, it is likely that smoking increased testosterone levels among those smoking regularly, although future research should explore potential casual relationships and measure serum testosterone at multiple timepoints to capture potential dynamic changes in relation to smoking behavior. In the present study, increased levels of estradiol increased the likelihood of quitting regular smoking; however, it was unrelated to relapse. This was contrary to the hypothesis that increased estradiol, which is generally associated with increased cravings, would be related to poorer smoking outcomes (i.e., less likely to transition to non-regular/no smoking and more likely to relapse to regular smoking). Previous research has asserted that estrogen is related to accelerated nicotine metabolism among pre-menopausal females; however, "menopausal" or postmenopausal females' nicotine metabolism does not differ from that of male smokers 32 . Thus, women across the menopausal transition may be less susceptible to the proposed effects of estradiol on smoking behavior.
However, additional investigation regarding ovarian hormones and smoking cessation is still warranted in this population, specifically with future studies collecting hormonal assays at multiple timepoints throughout the menopausal transition. There is emerging evidence that endogenous progesterone levels are related to smoking abstinence among pre-menopausal females 33 . It may be that progesterone, which decreases across the menopausal transition, also impacts transitions in smoking behaviors during the menopausal transition. Unfortunately, progesterone levels were not included in the publicly available, annual hormonal assays of the SWAN study; thus, the effect of progesterone and its metabolites (e.g., allopregnanolone) on smoking transitions were unable to be explored through this dataset 26 . Progesterone levels may also be needed to understand estrogen's effects on smoking behavior, as previous research has
shown that the ratio of progesterone to estradiol is a useful predictor of smoking behavior 16 .
An additional factor related to smoking outcomes among older females is depressive symptoms. Previous literature has established that negative affect and depression negatively impacts smoking cessation in postmenopausal women 7, 25 . The present study supported this Overall, while the present results did not demonstrate that menopausal status is associated to transitions in smoking behavior; they do illustrate that women are making transitions in smoking behavior as they age. Previous research among older smokers has shown that older smokers who are motivated to quit, have at least as high of a chance of quitting as their younger counterparts, especially when using nicotine replacement therapies 34 . This highlights the need to develop novel interventions to increase motivation to quit smoking and improve cessation outcomes among this population. Previous research has shown that menopausal symptom severity, including somatic menopausal symptoms (e.g., sweating/flush, cardiac complaints), was related to increased motivation to quit smoking 35 ; thus, evaluating one's health and menopausal symptomatology may increase motivation to quit smoking among postmenopausal women 35 . In future work, it may be beneficial to incorporate health evaluation into motivational-based interventions with this population. Additionally, addressing other potential barriers to cessation, including psychosocial stress may be advantageous. These avenues may offer important insight into the development of novel treatments for tobacco cessation for this population. A c c e p t e d M a n u s c r i p t 
